Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.

Also called NCT01237873

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 150 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01237873
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01237873. Allocation not applicable; no masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2012-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension
Condition
Essential Hypertension
Intervention (Drug)
Ali/Amlo 150/2.5 mg
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01237873
Content hash
d5baf9a3cfa4734960555c43cbcc8110b92c3a1e05d4b5644f1c5219c4b8c3e8